Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis

Double-blinded Placebo-controlled Multicenter Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01743404

Enrollment

300

Registered

2012-12-06

Start date

2007-09-30

Completion date

2013-06-30

Last updated

2012-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Atherosclerosis

Keywords

atherosclerosis, inflammation, intima-media thickness

Brief summary

The purpose of this study is to investigate the anti-atherosclerotic effect of long-term anti-inflammatory therapy (Inflaminat) in asymptomatic participants with subclinical atherosclerosis of carotid arteries.

Interventions

DIETARY_SUPPLEMENTInflaminat

DRUGPlacebo

Sugar pill manufactured to mimic Inflaminat 500 mg tablet

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

MALE

Age

40 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Men aged 40 to 70 years * Subclinical carotid atherosclerosis detected by B-mode ultrasound (increased intima-media thickness 1000-2000 mcm) * Arterial normotension or mild arterial hypertension (systolic blood pressure \<160 mm Hg, diastolic blood pressure \<90 mm Hg) * Absence of chronic diseases demanding permanent drug administration (more than 2 month per year)

Exclusion criteria

* Personal history of stroke or transient ischemic attacks * Chronic diseases demanding drug administration more than during 2 month per year * Individual intolerance of Inflaminat or appearance of side effects

Design outcomes

Primary

Measure	Time frame	Description
B-mode ultrasound of carotid arteries	up to 2 years	Variation of intima-media thickness of common carotid arteries

Secondary

Measure	Time frame	Description
Measure of serum atherogenicity	up to 2 years	Change of the ability of serum to induce cholesterol accumulation in cultured cells

Countries

Russia

Contacts

Primary ContactIgor Sobenin, MD

igor.sobenin@gmail.com+79263590050

Backup ContactEkaterina Chernova

katrincorde@gmail.com+79166647123

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026